Theravance, Inc. plans to separate its business into two independent publicly traded companies. The goal is to continue its businesses in a new structure designed to unlock potential value, facilitate return of capital and further its strategy to advancing medicines that address unmet medical needs.   Royalty Management Co. will manage all development and commercial responsibilities under its collaboration with GlaxoSmithKline and associated respiratory royalty revenues from Relvar or Breo Ellip...